Biocon and Mylan Launch Semglee (biosimilar, Insulin Glargine) in Australia

 Biocon and Mylan Launch Semglee (biosimilar, Insulin Glargine) in Australia

Biocon and Mylan Launch Semglee (biosimilar, Insulin Glargine) in Australia

Shots:

  • Biocon & Mylan launch the Semglee (insulin glargine solution for injection 100 IU/mL in a 3mL pre-filled pen) as the first Insulin Glargine biosimilar in Australia available on the PBS
  • The TGA approval is based on the data demonstrated high bio-similarity of Semglee with the reference, Insulin Glargine. The launch of Semglee will increase patients access to the therapy and reduces the cost burden for PBS
  • Insulin glargine (qd) is a long-acting basal insulin analog, helps to control the blood sugar levels in diabetes and is one of the three insulin analogs being co-developed by Mylan and Biocon. Mylan holds exclusive commercialization rights of Semglee in the US, Canada, Australia, New Zealand & EU while Biocon grasps exclusive commercialization rights in Japan & few emerging markets with co-exclusive commercialization rights with Mylan in ROW

Click here to­ read full press release/ article | Ref: Biocon | Image: Pinterest

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post